Cancer Family
Myeloid Neoplasm
CI-CAN-00000279Explore in graph →
HematologicNon-malignant1,103 active trials29 approved drugs653 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000279Explore in graph →
Clinical trials
4,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03241199 | The Efficacy and Safety of Induction-Maintenance Protocol for Patients With Chronic Myelogenous Leukaemia | unknown | Phase 2 | 15 | The University of Hong KongOTHER | 1 | Aug 8, 2017 | clinicaltrials |
| NCT02899286 | Efficacy and Safety Study of Recombinant Human Arginase 1 in Patients With Relapsed or Refractory Acute Myeloid Leukemia | unknown | Phase 2 | 25 | Bio-Cancer Treatment International LimitedINDUSTRY | 1 | Jul 28, 2017 |
| NCT03148197 | Changes in the Gut Microbiota of Patients Undergoing Allogeneic Stem Cell Transplantation (COLLECT)(COLLECT) | unknown | — | 120 | University of CologneOTHER | 1 | Jul 19, 2017 | clinicaltrials |
| NCT03216070 | Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia | unknown | Phase 4 | 12 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Jul 13, 2017 | clinicaltrials |
| NCT02802267 | Efficacy Study of Inecalcitol With Decitabine in Acute Myeloid Leukemia Patients Unfit for Standard Chemotherapy | unknown | Phase 2 | 110 | Hybrigenics CorporationINDUSTRY | 2 | Jul 2, 2017 | clinicaltrials |
| NCT03204838 | IDH1/IDH2 Mutation Frequency in Acute Myeloblastic Patients | unknown | — | 100 | Hospital General de MexicoOTHER_GOV | 1 | Jul 2, 2017 | clinicaltrials |
| NCT03205267 | Phase II Study Testing the Tolerability and the Efficacy of Bosutinib in Chronic Phase CML Patients(BODO) | unknown | Phase 2 | 127 | University of BonnOTHER | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01520558 | CNDO-109-AANK for AML in First Complete Remission (CR1) | unknown | Phase 1 / Phase 2 | 12 | Coronado Biosciences, Inc.INDUSTRY | 1 | Jun 29, 2017 | clinicaltrials |
| NCT03114670 | Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT | unknown | Phase 1 | 20 | Affiliated Hospital to Academy of Military Medical SciencesOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT03177928 | Cardiac Changes in Myeloproliferative Neoplasms | unknown | N/A | 40 | Assiut UniversityOTHER | 0 | Jun 6, 2017 | clinicaltrials |
| NCT03156933 | Alternative Splicing and Leukemia Initiating Cells(ASLIC) | unknown | — | 500 | Hospices Civils de LyonOTHER | 1 | May 17, 2017 | clinicaltrials |
| NCT03150134 | Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients | unknown | Phase 4 | 100 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 12, 2017 | clinicaltrials |
| NCT02493829 | B7.1/IL-2 Leukaemia Cell Vaccine for Non-Transplant AML RFUSIN2-AML2 (NTX) | unknown | Phase 1 | 10 | King's College LondonOTHER | 0 | Apr 13, 2017 | clinicaltrials |
| NCT03080922 | High Dose Donor Hematopoietic Stem Cell Infusion for Relapsed/Refractory AML | unknown | Phase 1 / Phase 2 | 10 | The Affiliated Hospital of the Chinese Academy of Military Medical SciencesOTHER | 1 | Apr 4, 2017 | clinicaltrials |
| NCT02863302 | Reflexology: An Intervention for Acute Myeloid Leukemia(AML) Patients | unknown | N/A | 50 | Rambam Health Care CampusOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT03053206 | A Prospective, Interventional Study Assessing Response to Cytarabine, Daunorubicin and Etoposide (ADE) for First Relapse of Paediatric Acute Myeloid Leukemia | unknown | Phase 2 | 84 | All India Institute of Medical SciencesOTHER | 0 | Feb 15, 2017 | clinicaltrials |
| NCT03045627 | Clinical Trial of Ara-C, Aclarubicin Combined With PEG-G-CSF for Initial Treatment of AML Patients | unknown | Phase 2 | 120 | Shandong UniversityOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT03023384 | Feasibility Study of Intermediate Doses of ARA-C With Autologous SCT as Consolidation of Low/Intermediate-risk AML(ICAML2015) | unknown | — | 547 | International Consortium on Acute LeukemiasOTHER | 1 | Feb 3, 2017 | clinicaltrials |
| NCT01226303 | Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia | unknown | Phase 3 | 300 | Associazione Italiana Ematologia Oncologia PediatricaOTHER | 1 | Jan 26, 2017 | clinicaltrials |
| NCT02979548 | Study to Evaluate the Effect of Aprepitant in Children and Adolescents Receiving AML Remission Induction Chemotherapy | unknown | Phase 3 | 116 | Dr Atul SharmaOTHER | 1 | Jan 25, 2017 | clinicaltrials |
| NCT03026842 | Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21) | unknown | Phase 4 | 180 | The First Hospital of Jilin UniversityOTHER | 1 | Jan 20, 2017 | clinicaltrials |
| NCT01828489 | Research Study for Treatment of Children and Adolescents With Acute Myeloid Leukaemia 0-18 Years(AML2012) | unknown | Phase 3 | 300 | Vastra Gotaland RegionOTHER_GOV | 9 | Jan 10, 2017 | clinicaltrials |
| NCT02985372 | Decitabine in Combination With Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia | unknown | Phase 3 | 30 | Chunyan JiOTHER | 0 | Dec 7, 2016 | clinicaltrials |
| NCT02742727 | CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02944162 | CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02975115 | Evaluating True PCR-negative Rate of Frontline Dasatinib in Early Chronic Phase CML for Therapeutic Harmonization | unknown | — | 102 | Seoul St. Mary's HospitalOTHER | 0 | Nov 29, 2016 | clinicaltrials |
| NCT02949570 | Study to Assess Efficacy and Safety of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM Study(ICT10) | unknown | Phase 2 | 54 | Hybrigenics CorporationINDUSTRY | 1 | Oct 31, 2016 | clinicaltrials |
| NCT02432872 | Treatment of Older Adult Acute Myeloid Leukemia Patients Aged 55 to 65 Years | unknown | N/A | 300 | Jianxiang WangUNKNOWN | 1 | Oct 7, 2016 | clinicaltrials |
| NCT02432911 | Treatment of Elderly Chinese Acute Myeloid Leukemia Patients Aged 65 to 75 Years Old | unknown | N/A | 300 | Jianxiang WangUNKNOWN | 1 | Oct 7, 2016 | clinicaltrials |
| NCT02027064 | Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT | unknown | Phase 4 | 40 | Peking University People's HospitalOTHER | 1 | Sep 29, 2016 | clinicaltrials |
| NCT01758367 | Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia(AML) After Allogeneic Stem Cell Transplantation | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Aug 31, 2016 | clinicaltrials |
| NCT02883036 | Vitro Study of Tigecycline to Treat Chronic Myeloid Leukemia | unknown | — | 100 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Aug 30, 2016 | clinicaltrials |
| NCT01602939 | Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis | unknown | Phase 2 / Phase 3 | 10 | Hospital Virgen de la SaludOTHER | 1 | Aug 29, 2016 | clinicaltrials |
| NCT02859948 | A Study of SKLB1028 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia | unknown | Phase 1 | 18 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Aug 9, 2016 | clinicaltrials |
| NCT02860598 | Observatory of the Prescription of Erythropoietin as Treatment of Anemia Induced by Chemotherapy or Allograft Conditioning Among the Patients With a Haematological Malignancy(EPREX/LAM-ALLO) | unknown | — | 104 | Hospices Civils de LyonOTHER | 1 | Aug 9, 2016 | clinicaltrials |
| NCT02848183 | Optimal Treatment Strategy Based on for Pediatric AML | unknown | Phase 2 | 350 | Samsung Medical CenterOTHER | 1 | Jul 28, 2016 | clinicaltrials |
| NCT01146262 | Vaccination by Leukemic Apoptotic Corpse Autologous Pulsed Dendritic Cells for Acute Myelogenous Leukemia (AML) Patients in First or Second Complete Remission (CR)(CD laM)(CD lam) | unknown | Phase 1 / Phase 2 | 5 | Nantes University HospitalOTHER | 1 | Jul 26, 2016 | clinicaltrials |
| NCT01484171 | HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia | unknown | Phase 3 | 50 | The Affiliated Hospital of the Chinese Academy of Military Medical SciencesOTHER | 1 | Jul 13, 2016 | clinicaltrials |
| NCT02171117 | Safety and Efficacy Study of Microtransplantation to Treat Elderly Acute Myeloid Leukemia(IMCG-EAML) | unknown | Phase 3 | 196 | The Affiliated Hospital of the Chinese Academy of Military Medical SciencesOTHER | 1 | Jul 13, 2016 | clinicaltrials |
| NCT02809274 | Incidence of Iron Deficiency in Polycythemia Vera (PV) and Association With Disease Features | unknown | — | 200 | Rambam Health Care CampusOTHER | 1 | Jun 22, 2016 | clinicaltrials |
| NCT01690065 | Nilotinib-Chemotherapy in CML Myeloid BP or Bcr-abl(+) AML(NICE-BORA) | unknown | Phase 2 | 46 | Ulsan University HospitalOTHER | 1 | May 11, 2016 | clinicaltrials |
| NCT02422719 | Radotinib as 3rd or Later Line Therapy in CP-CML(REVITAL) | unknown | Phase 2 | 73 | Ulsan University HospitalOTHER | 1 | May 11, 2016 | clinicaltrials |
| NCT02244658 | Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia | unknown | Phase 3 | 80 | Shandong UniversityOTHER | 1 | Apr 20, 2016 | clinicaltrials |
| NCT02240537 | Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer(BBMPI03) | unknown | Phase 1 | 4 | Benovus Bio, Inc.INDUSTRY | 1 | Apr 19, 2016 | clinicaltrials |
| NCT02698124 | Decitabine for Chemotherapy Unfit Korean AML Patients in Real Practice(PURPLE-D) | unknown | — | 136 | Ulsan University HospitalOTHER | 1 | Mar 7, 2016 | clinicaltrials |
| NCT02413021 | The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens | unknown | Phase 1 | 40 | Isfahan University of Medical SciencesOTHER | 0 | Feb 25, 2016 | clinicaltrials |
| NCT01864902 | Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33(CART33) | unknown | Phase 1 / Phase 2 | 10 | Chinese PLA General HospitalOTHER | 1 | Jan 28, 2016 | clinicaltrials |
| NCT01277484 | Dose Finding Study of Post-BMT Decitabine Maintenance Treatment in Higher-risk MDS and MDS/AML(PODAC) | unknown | Phase 1 | 19 | Seoul St. Mary's HospitalOTHER | 1 | Nov 20, 2015 | clinicaltrials |
| NCT02189824 | Chemotherapy Followed by Infusion of Partially HLA Matched Unrelated Donor Cells for Patients With AML Who Are Ineligible for Stem Cell Transplantation(SCRAMBLE) | unknown | Phase 1 | 12 | University of SydneyOTHER | 1 | Nov 2, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Aug 8, 2017source: clinicaltrials